Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment

Paolo Vercellini; P Vercellini; Vendola N; Nicoletta Vendola; N Vendola; A. Colombo; Alberto Colombo; Colombo A; Cristina Passadore; Passadore C; C Passadore; Laura Trespìdi; Trespidi L; L Trespidi; Crosignani PG; P. G. Crosignani; Pier Giorgio Crosignani

doi:10.1159/000292736

Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment

Paolo Vercellini, P Vercellini, Vendola N, Nicoletta Vendola, N Vendola, A. Colombo, Alberto Colombo, Colombo A, Cristina Passadore, Passadore C, C Passadore, Laura Trespìdi, Trespidi L, L Trespidi, Crosignani PG, P. G. Crosignani, Pier Giorgio Crosignani

Gynecologic and obstetric investigation · 2010 · vol. 34(2) , pp. 102–104 · doi:10.1159/000292736 · PMID:1398260 · W2061346474

Non-randomised trial OA: closed CC0 ⤵ 1 in-corpus citation

View on OpenAlex View on PubMed View at publisher

⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-28 ⓘ

Veralipride treatment improved hot flush frequency and intensity in 92% of premenopausal women receiving gonadotropin-releasing hormone agonist therapy for endometriosis or menorrhagia.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Hot flushes are the commonest symptom induced by gonadotropin-releasing hormone agonists (GnRHa). We performed an open observational trial to evaluate the efficacy of veralipride, an antidopaminergic drug, in reducing hot flushes in 25 premenopausal women treated with a GnRHa for endometriosis (8 subjects) or menorrhagia (17 subjects). The patients received goserelin depot for 6 months and veralipride was added for the third month. Hot flushes, severe in all women at 2 months, improved in both frequency and intensity in 92% of the subjects during veralipride administration. The benefit obtained persisted until the end of the GnRHa treatment.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Flushing Goserelin Menorrhagia Sulpiride Adult Adult Drug Therapy, Combination Drug Therapy, Combination Endometriosis Endometriosis Endometriosis Estradiol Estradiol Estradiol Female Female Flushing Flushing Flushing

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders 1996

Cited by (1)

Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders 1996

Source provenance

europepmc: last seen: 2026-11-04T06:09:08.831786+00:00
openalex: last seen: 2026-06-04T00:00:01.174412+00:00
pubmed: last seen: 2026-10-08T21:01:48.093215+00:00
unpaywall: last seen: 2026-11-05T06:08:55.941966+00:00

License: CC0 · commercial use OK